The GLP is committed to full transparency. Download and review our Annual Report.

Scientists find ‘glimmer of hope’ in early HIV vaccine trial

| | July 17, 2018

There may be a glimmer of hope in the fight to protect people from HIV-1, the most widespread type of the virus and the one that causes the most disease globally.

A new vaccine appears to be safe and induced an immune response in humans and rhesus monkeys in an early stage trial, according to new research published [July 6] in the journal The Lancet.

That means it’s safe enough to go into the next phase of testing, which involves a larger number of humans. It’s one of only five experimental HIV-1 vaccine concepts that have gotten this far.

In addition to being well-tolerated by all the test subjects and inducing an immune response against HIV in humans, the vaccine provided 67% protection against infection from the simian-human immunodeficiency virus in the rhesus monkeys.

Related article:  Cancer-linked obesity soaring among millennials in the United States

Researchers caution that the results of the early trial do not mean a viable vaccine. The ability to induce HIV-specific immune responses does not necessarily mean the vaccine will protect humans from HIV infection.

“Despite all the advances we have had with HIV, we need a vaccine. It is critical, and this new vaccine, while there is a long way to go, it is nice to see robust evidence to move on to the next phase of testing,” [said researcher Carlos del Rio].

Read full, original post: Scientists cautiously optimistic about HIV vaccine candidate

The GLP aggregated and excerpted this article to reflect the diversity of news, opinion, and analysis. Click the link above to read the full, original article.
News on human & agricultural genetics and biotechnology delivered to your inbox.
Optional. Mail on special occasions.

Send this to a friend